Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2024

View source ↗

Summary

EMA PRAC meeting highlights that metamizole carries a risk of serious blood disorders. It recommends measures to minimize these risks and protect patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fever
• Pain

Drugs mentioned

• Analgin (metamizole)
• Metamizole (metamizole)

Snippet

EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizole